Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Pune, Jan. 21, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Sleep Apnea Devices Market size was valued at USD 5.25 billion in 2023 and is expected to reach USD 9.43 billion by 2032 ...

A new analysis published in Otolaryngology–Head and Neck Surgery reveals that for people with sleep apnea, getting surgery for their condition may lessen their risk of such accidents compared ...